A rationale for an individualized administration frequency of epoetin β: A clinical perspective

Nephrology Dialysis Transplantation

Volumn 17, Issue SUPPL. 6, 2002, Pages 8-12

  Weiss, Lars ^a  

^a Centralsjukhuset   (Sweden)

Author keywords

Delivery device; Dosing frequency; Epoetin ; Patient education; Self administration; Subcutaneous

Indexed keywords

IRON; RECOMBINANT ERYTHROPOIETIN; ERYTHROPOIETIN;

ANEMIA; ARTICLE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DOSE CALCULATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; DRUG SELF ADMINISTRATION; HUMAN; INTERMETHOD COMPARISON; PATIENT COMPLIANCE; PATIENT EDUCATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; DRUG ADMINISTRATION; HEMATOCRIT; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION;

DRUG ADMINISTRATION SCHEDULE; ERYTHROPOIETIN; HEMATOCRIT; HUMAN; INJECTIONS, SUBCUTANEOUS; PATIENT EDUCATION; SELF ADMINISTRATION; ERYTHROPOIETIN, RECOMBINANT; HUMANS;

EID: 0036325265     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Left ventricular mass index increase in early renal disease: Impact of decline in hemoglobin
2. Cardiovascular effects of recombinant human erythropoietin in predialysis patients
3. Cardiovascular effect of normalizing the hematocrit level during erythropoietin therapy in predialysis patients with chronic renal failure
4. Improvement and prevention of left ventricular hypertrophy in predialysis patients
5. Clinical Practice Guidelines for the treatment of anemia of chronic renal failure
6. Clinical Practice Guidelines for anemia of chronic kidney disease: Update 2000
7. European Best Practice Guidelines for the management of anaemia in patients with chronic renal failure
8. Dose-related effects of recombinant human erythropoietin on erythropoiesis. Results of a multicenter trial in patients with end-stage renal disease
9. Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial
10. Subcutaneous versus intravenous administration of erythropoietin improves its efficiency for the treatment of anaemia in haemodialysis patients
11. Clinical pharmacology and economics of recombinant human erythropoietin in end-stage renal renal disease: The case for subcutaneous administration
12. The haematopoietic effect of recombinant human erythropoietin in haemodialysis is independent of the mode of administration (i.v. or s.c.)
13. Intravenous versus subcutaneous administration of recombinant human erythropoietin in patients on haemodialysis and CAPD
14. Comparison of dose requirement, serum erythropoietin and blood pressure following intravenous and subcutaneous erythropoietin treatment of dialysis patients. IV and SC erythropoietin
15. Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis
16. Comparison of subcutaneous and intravenous recombinant human erythropoietin for anemia in hemodialysis patients with significant comorbid disease
17. Intravenous versus subcutaneous dosing of epoetin alfa in hemodialysis patients
18. Safety and efficacy of low-dose subcutaneous erythropoietin in hemodialysis patients
19. Differences in intravenous and subcutaneous application of recombinant human erythropoietin: A multicenter trial
20. Erythropoietin response and route of administration
21. Must erythropoietin be injected by the subcutaneous route for every hemodialyzed patient?
22. Recombinant human erythropoietin in anemic patients on maintenance hemodialysis: Comparison between intravenous and subcutaneous administration
23. European Best Practice Guidelines 9-13: Anaemia management
24. Once weekly versus twice weekly subcutaneous administration of recombinant human erythropoietin in haemodialysis patients
25. What is the optimum frequency of administration of r-HuEPO for correcting anemia in hemodialysis patients?
26. Efficacy of recombinant human erythropoietin administered subcutaneously to CAPD patients once weekly
27. Efficiency of once-weekly subcutaneous administration of recombinant human erythropoietin versus three times a week administration in hemodialysis patients
28. The efficacy of once weekly compared with two or three times weekly subcutaneous epoetin β: Results from a randomized controlled multicentre trial
29. 25% reduction of erythropoietin (EPO) dose in haemodialysis (HD) patients with the Reco-Pen®
30. Tolerability of the epoetin-beta multidose formulation (Reco-Pen®) in patients with renal anaemia
31. Tolerability and safety of multidose® epoetin beta (Reco-Pen®) for subcutaneous administration in patients with anaemia due to renal failure
32. The role of patients in the implementation of the National Kidney Foundation-Dialysis Outcomes Quality Initiative
33. Multidisciplinary predialysis programs: Quantification and limitations of their impact on patient outcomes in two Canadian settings
34. Once weekly compared with three times weekly subcutaneous epoetin β: Results from a randomized, multicenter, therapeutic equivalence study